Consumers First’s 2021 Administrative Agenda Calls on President Biden to Address Health Care’s Inefficiencies, Inequities, and Market Failures.
Comptroller General of the United States and head of the U.S. Government Accountability Office (GAO), today announced the appointment of six members, including PBGH’s Emma Hoo, to the newly created State All Payer Claims Databases Advisory Committee (SAPCDAC).
Participating organizations serve over 750,000 patients across California’s Central Valley and Inland Empire, where patients with diabetes and asthma have poorer clinical outcomes compared to the rest of the state.
PBGH CEO, Elizabeth Mitchell, testifies on telehealth and its rapid adoption during the pandemic to the House Committee on Energy & Commerce, Subcommittee on Health.
PBGH offers its strong support for the nomination of Xavier Becerra for Secretary of the Department of Health and Human Services.
PBGH joined 25 other organizations representing many of the nation’s leading private and public sector employers, to offer recommendations for forthcoming legislation to mitigate the COVID-pandemic and restore our economy.
Now Purchaser Business Group on Health, PBGH has changed its name to reflect its national presence and purchaser-only membership.
On Friday, July 24, the President signed four executive orders aimed at reducing prescription drug prices. While executive orders do not need congressional approval, each of these orders requires further rulemaking and are thus not immediately enforceable. In addition, all four orders will be fought in the courts by affected stakeholders and the orders could be withdrawn by a future administration. Nevertheless, if ever finalized, the orders could have a significant impact on drug costs in the future.
PBGH’s California Quality Collaborative hosted leading voices in health reform to address enhanced access to health care beyond the pandemic.
Read the statement.
As the COVID-19 crisis will only end when people have access to effective vaccines and therapeutic drugs, EmployersRx urges legislators, manufacturers and providers to ensure fair and reasonable pricing of these shortly anticipated treatments.